2020
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, Adlard J, Ahmed M, Aittomäki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Benitez J, Berthet P, Białkowska K, Blanco AM, Blok MJ, Bonanni B, Boonen SE, Borg Å, Bozsik A, Bradbury AR, Brennan P, Brewer C, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Christensen LL, Chung WK, Claes KBM, Colas C, Collonge-Rame M, Cook J, Daly M, Davidson R, de la Hoya M, de Putter R, Delnatte C, Devilee P, Diez O, Ding Y, Domchek S, Dorfling C, Dumont M, Eeles R, Ejlertsen B, Engel C, Evans D, Faivre L, Foretova L, Fostira F, Friedlander M, Friedman E, Frost D, Ganz P, Garber J, Gehrig A, Gerdes A, Gesta P, Giraud S, Glendon G, Godwin A, Goldgar D, González-Neira A, Greene M, Gschwantler-Kaulich D, Hahnen E, Hamann U, Hanson H, Hentschel J, Hogervorst F, Hooning M, Horvath J, Hu C, Hulick P, Imyanitov E, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, John E, Joseph V, Karlan B, Kast K, Koudijs M, Kruse T, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Lesueur F, Liljegren A, Loud J, Lubiński J, Mai P, Manoukian S, Mari V, Mebirouk N, Meijers-Heijboer H, Meindl A, Mensenkamp A, Miller A, Montagna M, Mouret-Fourme E, Mukherjee S, Mulligan A, Nathanson K, Neuhausen S, Nevanlinna H, Niederacher D, Nielsen F, Nikitina-Zake L, Noguès C, Olah E, Olopade O, Ong K, O’Shaughnessy-Kirwan A, Osorio A, Ott C, Papi L, Park S, Parsons M, Pedersen I, Peissel B, Peixoto A, Peterlongo P, Pfeiler G, Phillips K, Prajzendanc K, Pujana M, Radice P, Ramser J, Ramus S, Rantala J, Rennert G, Risch H, Robson M, Rønlund K, Salani R, Schuster H, Senter L, Shah P, Sharma P, Side L, Singer C, Slavin T, Soucy P, Southey M, Spurdle A, Steinemann D, Steinsnyder Z, Stoppa-Lyonnet D, Sutter C, Tan Y, Teixeira M, Teo S, Thull D, Tischkowitz M, Tognazzo S, Toland A, Trainer A, Tung N, van Engelen K, van Rensburg E, Vega A, Vierstraete J, Wagner G, Walker L, Wang-Gohrke S, Wappenschmidt B, Weitzel J, Yadav S, Yang X, Yannoukakos D, Zimbalatti D, Offit K, Thomassen M, Couch F, Schmutzler R, Simard J, Easton D, Chenevix-Trench G, Antoniou A. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics In Medicine 2020, 22: 1653-1666. PMID: 32665703, PMCID: PMC7521995, DOI: 10.1038/s41436-020-0862-x.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerPathogenic variant carriersProspective cohortPolygenic risk scoresVariant carriersCancer riskRisk scoreStrong associationEOC riskHigh-grade serous epithelial ovarian cancerSerous epithelial ovarian cancerER-positive BCBRCA2 pathogenic variantsCarriers of BRCA1Absolute risk differenceEpithelial ovarian cancer riskGeneral population estimatesOvarian cancer riskHR estimatesBRCA2 pathogenic variant carriersBRCA1 carriersBRCA1/2 carriersOvarian cancerBC riskEstrogen receptor
2016
Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study
Ong JS, Cuellar-Partida G, Lu Y, Study A, Fasching P, Hein A, Burghaus S, Beckmann M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty J, Rossing M, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman M, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum I, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari L, Edwards R, Kelley J, Modugno F, Moysich K, Ness R, Cannioto R, Høgdall E, Høgdall C, Jensen A, Giles G, Bruinsma F, Kjaer S, Hildebrandt M, Liang D, Lu K, Wu X, Bisogna M, Dao F, Levine D, Cramer D, Terry K, Tworoger S, Stampfer M, Missmer S, Bjorge L, Salvesen H, Kopperud R, Bischof K, Aben K, Kiemeney L, Massuger L, Brooks-Wilson A, Olson S, McGuire V, Rothstein J, Sieh W, Whittemore A, Cook L, Le N, Gilks C, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Song H, Tyrer J, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin J, Narod S, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther S, Gentry-Maharaj A, Menon U, Ramus S, Wu A, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham J, Fridley B, Winham S, Bandera E, Poole E, Morgan T, Risch H, Goode E, Schildkraut J, Pearce C, Berchuck A, Pharoah P, Chenevix-Trench G, Gharahkhani P, Neale R, Webb P, MacGregor S. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal Of Epidemiology 2016, 45: 1619-1630. PMID: 27594614, PMCID: PMC5100621, DOI: 10.1093/ije/dyw207.Peer-Reviewed Original ResearchConceptsVitamin D levelsOvarian cancerVitamin DD levelsOdds ratioObservational studySingle nucleotide polymorphismsD concentrationsPlasma vitamin D levelsHigh-grade serous ovarian cancerHigh-grade serous epithelial ovarian cancerMendelian randomizationSerous epithelial ovarian cancerEpithelial ovarian cancer riskEpithelial ovarian cancerOvarian cancer riskOvarian Cancer Association ConsortiumSerous ovarian cancerObservational epidemiological studiesTwo-sample MR approachInverse variance weightingMendelian randomization studyOvarian cancer susceptibilityCancer preventionCancer riskChronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk
Cannioto R, LaMonte M, Risch H, Hong C, Sucheston-Campbell L, Eng K, Szender J, Chang-Claude J, Schmalfeldt B, Klapdor R, Gower E, Minlikeeva A, Zirpoli G, Bandera E, Berchuck A, Cramer D, Doherty J, Edwards R, Fridley B, Goode E, Goodman M, Hogdall E, Hosono S, Jensen A, Jordan S, Kjaer S, Matsuo K, Ness R, Olsen C, Olson S, Pearce C, Pike M, Rossing M, Szamreta E, Thompson P, Tseng C, Vierkant R, Webb P, Wentzensen N, Wicklund K, Winham S, Wu A, Modugno F, Schildkraut J, Terry K, Kelemen L, Moysich K. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk. Obstetrical & Gynecological Survey 2016, 71: 528-530. DOI: 10.1097/ogx.0000000000000357.Peer-Reviewed Original ResearchChronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium
Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE, Eng KH, Szender JB, Chang-Claude J, Schmalfeldt B, Klapdor R, Gower E, Minlikeeva AN, Zirpoli GR, Bandera EV, Berchuck A, Cramer D, Doherty JA, Edwards RP, Fridley BL, Goode EL, Goodman MT, Hogdall E, Hosono S, Jensen A, Jordan S, Group O, Kjaer S, Matsuo K, Ness R, Olsen C, Olson S, Pearce C, Pike M, Rossing M, Szamreta E, Thompson P, Tseng C, Vierkant R, Webb P, Wentzensen N, Wicklund K, Winham S, Wu A, Modugno F, Schildkraut J, Terry K, Kelemen L, Moysich K. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2016, 25: 1114-1124. PMID: 27197285, PMCID: PMC4930728, DOI: 10.1158/1055-9965.epi-15-1330.Peer-Reviewed Original ResearchConceptsRecreational physical inactivityRecreational physical activityPhysical inactivityEOC riskPooled analysisPhysical activityWeekly recreational physical activityLarge pooled analysisIndependent risk factorEpithelial ovarian cancer riskPhysical activity guidelinesBody mass indexMultivariable logistic regressionConfidence intervalsOvarian cancer riskOvarian Cancer Association ConsortiumDose of activityMenopausal statusChronic inactivityActivity guidelinesEOC patientsMass indexSignificant positive associationBody of evidenceIndependent association
2015
Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk
Amankwah EK, Lin H, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, Anton‐Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks‐Wilson A, Bunker CH, Butzow R, Campbell IG, Carty K, Chen Z, Chen YA, Chang‐Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka‐Mieszkowska A, du Bois A, Despierre E, Dicks E, Doherty JA, Dörk T, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao Y, Gentry‐Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall CK, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji B, Karlan BY, Jim H, Kellar M, Kiemeney LA, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lim BK, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Eilber U, Odunsi K, Olson SH, Orlow I, Orsulic S, Weber RP, Paul J, Pearce CL, Pejovic T, Pelttari LM, Permuth‐Wey J, Pike MC, Poole EM, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schernhammer E, Schwaab I, Shu X, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston‐Campbell L, Teo S, Terry KL, Thompson PJ, Thomsen L, Tangen IL, Tworoger SS, van Altena A, Vierkant RA, Vergote I, Walsh CS, Wang‐Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo Y, Yang H, Zheng W, Ziogas A, Kelemen LE, Berchuck A, group G, Schildkraut J, Ramus S, Goode E, Monteiro A, Gayther S, Narod S, Pharoah P, Sellers T, Phelan C. Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology 2015, 39: 689-697. PMID: 26399219, PMCID: PMC4721602, DOI: 10.1002/gepi.21921.Peer-Reviewed Original Research
2013
Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls
Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH, Cushing-Haugen K, Sieh W, Moysich K, Doherty JA, Nagle CM, Berchuck A, Pearce CL, Pike M, Ness RB, Webb PM, Study A, Rossing M, Schildkraut J, Risch H, Goodman M. Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls. Cancer Prevention Research 2013, 6: 811-821. PMID: 23761272, PMCID: PMC3766843, DOI: 10.1158/1940-6207.capr-13-0037.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerPowder usePopulation-based case-control studyMost histologic subtypesEpithelial ovarian cancer riskBorderline serous tumorsOvarian cancer riskCase-control studySubtype-specific riskConditional logistic regressionHistologic subtypeHistologic typeSerous tumorsPotential confoundersPooled analysisPooled ORsModifiable exposuresCancer riskTumor behaviorEpidemiologic investigationsCancerLogistic regressionLifetime numberCarcinogenic effectsEpigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer
Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M, Ziogas A, Zheng W, Yang H, Wu A, Wozniak E, Ling Woo Y, Winterhoff B, Wik E, Whittemore A, Wentzensen N, Palmieri Weber R, Vitonis A, Vincent D, Vierkant R, Vergote I, Van Den Berg D, Van Altena A, Tworoger S, Thompson P, Tessier D, Terry K, Teo S, Templeman C, Stram D, Southey M, Sieh W, Siddiqui N, Shvetsov Y, Shu X, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen H, Rzepecka I, Runnebaum I, Anne Rossing M, Rodriguez-Rodriguez L, Risch H, Renner S, Poole E, Pike M, Phelan C, Pelttari L, Pejovic T, Paul J, Orlow I, Zawiah Omar S, Olson S, Odunsi K, Nickels S, Nevanlinna H, Ness R, Narod S, Nakanishi T, Moysich K, Monteiro A, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin J, McGuire V, Matsuo K, Mat Adenan N, Massuger L, Lurie G, Lundvall L, Lubiński J, Lissowska J, Levine D, Leminen A, Lee A, Le N, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny G, Krüger Kjaer S, Kiemeney L, Kelemen L, Keeney G, Karlan B, Karevan R, Kalli K, Kajiyama H, Ji B, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall C, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle M, Hall P, Gronwald J, Gore M, Goodman M, Giles G, Gentry-Maharaj A, Garcia-Closas M, Flanagan J, Fasching P, Ekici A, Edwards R, Eccles D, Easton D, Dürst M, du Bois A, Dörk T, Doherty J, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer D, Cook L, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker C, Brueggmann D, Brown R, Brooks-Wilson A, Brinton L, Bogdanova N, Block M, Benjamin E, Beesley J, Beckmann M, Bandera E, Baglietto L, Bacot F, Armasu S, Antonenkova N, Anton-Culver H, Aben K, Liang D, Wu X, Lu K, Hildebrandt M, Schildkraut J, Sellers T, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther S, Pharoah P, Laird P, Goode E, Leigh Pearce C. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications 2013, 4: 1628. PMID: 23535649, PMCID: PMC3848248, DOI: 10.1038/ncomms2629.Peer-Reviewed Original ResearchConceptsDNA methylationAnalyse DNA methylationClear cell epithelial ovarian cancerSingle nucleotide polymorphismsEpigenetic analysisExpression patternsExpression profilesDifferent single nucleotide polymorphismsCpG island methylator phenotypeSusceptibility genesMethylationDistinct mechanismsGenesMethylator phenotypeHNF1BOvarian cancerRisk allelesSerous epithelial ovarian cancerEpithelial ovarian cancerAssociatesEpithelial ovarian cancer riskGenomePromoterPhenotypeAlleles